2,4,6-trifluorobenzimidamide | 1005460-15-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4,6-trifluorobenzimidamide
• 英文别名: 2,4,6-trifluorobenzenecarboximidamide
• CAS: 1005460-15-0
• 化学式: C₇H₅F₃N₂
• mdl: MFCD09745451
• 分子量: 174.125
• InChiKey: CYZIWQQIIHNZKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,4,6-三氟苯腈 在 三甲基铝 、 氯化铵 作用下， 以 甲苯 为溶剂， 以45%的产率得到2,4,6-trifluorobenzimidamide
  参考文献：
  名称：

  [EN] HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  [FR] DÉRIVÉS HÉTÉROARYLDIHYDROPYRIMIDINE ET MÉTHODES DE TRAITEMENT D'INFECTIONS PAR LE VIRUS DE L'HÉPATITE B

  摘要：

  本文提供了一些用于治疗HBV感染的化合物，以及其药物组合物和抑制、抑制或预防受试者HBV感染的方法。

  公开号：

  WO2019001420A1

文献信息

• DIHYDROPYRIMIDINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Li Song

  公开号：US20120149695A1

  公开（公告）日：2012-06-14

  Disclosed are dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof. Specifically, the compounds described herein in general formula (I), or their isomers, pharmaceutically acceptable salts or hydrates are provided, wherein each variable has the meaning as defined in the description. Also provided are a process for preparing the compounds of the general formula (I), the use of the compounds, an isomer thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof as a medicament, in particular as a medicament for the treatment and/or prevention of Hepatitis B.

  本文揭示了二氢嘧啶化合物及其制备方法、药物组合物及其用途。具体地，提供了一般式（I）中描述的化合物，或其异构体、药学上可接受的盐或水合物，其中每个变量的含义如描述中所定义。还提供了制备一般式（I）化合物的方法，以及将这些化合物、其异构体、药学上可接受的盐或水合物用作药物的用途，特别是作为治疗和/或预防乙型肝炎的药物。
• Optically Pure Dihydropyrimidine Compounds and Their Uses for the Preparation of a Medicament for Treatment and Prevention of Viral Diseases
  申请人：Li Song

  公开号：US20100004268A1

  公开（公告）日：2010-01-07

  The present invention relates to an optically pure compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, a process for preparing the optically pure compound of formula (I), and use of the optically pure compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis.

  本发明涉及公式(I)的光学纯化合物或其药学上可接受的盐或水合物，制备公式(I)的光学纯化合物的方法，以及将公式(I)的光学纯化合物或其药学上可接受的盐或水合物用作药物，特别是用作治疗和预防B型肝炎的药物。
• OPTICAL PURE DIHYDROPYRIMIDINE COMPOUNDS, THEIR USES IN THE MANUFACTURE OF A MEDICAMNENT FOR THE TREATMENT OR THE PREVENTION OF VIROSIS DISEASES
  申请人：Beijing Molecule Science and Technology Co., Ltd.

  公开号：EP2048141A1

  公开（公告）日：2009-04-15

  The present invention relates to an optically pure compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, a process for preparing the optically pure compound of formula (I), and use of the optically pure compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis.

  本发明涉及一种光学纯的式(I)化合物或其药学上可接受的盐或水合物、制备光学纯的式(I)化合物的工艺，以及将光学纯的式(I)化合物或其药学上可接受的盐或水合物用作药物，特别是用作治疗和预防乙型肝炎的药物。
• DIHYDROPYRIMIDINE COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE AS ANTIVIRAL AGENTS
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

  公开号：EP2447253B1

  公开（公告）日：2014-06-18
• OPTICALLY PURE DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES FOR THE PREPARATION OF A MEDICAMENT FOR TREATMENT AND PREVENTION OF VIRAL DISEASES.
  申请人：Beijing Molecule Science and Technology Co., Ltd.

  公开号：EP2048141B1

  公开（公告）日：2017-06-14